Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.
作者信息
Alkhateeb Hassan B, Mohty Razan, Greipp Patricia, Bansal Radhika, Hathcock Matthew, Rosenthal Allison, Murthy Hemant, Kharfan-Dabaja Mohamed, Bisneto Villasboas Jose C, Bennani Nora, Ansell Stephen M, Patnaik Mrinal M, Litzow Mark R, He Rong, Chen Dong, Al-Kali Aref, Kenderian Saad S, Lin Yi, Shah Mithun Vinod
机构信息
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
Department of Hematology/Oncology, Mayo Clinic, Jacksonville, FL, USA.
出版信息
Blood Cancer J. 2022 Jul 26;12(7):113. doi: 10.1038/s41408-022-00707-4.
Abstract
摘要
相似文献
1
Therapy-related myeloid neoplasms following chimeric antigen receptor T-cell therapy for Non-Hodgkin Lymphoma.
Blood Cancer J. 2022 Jul 26;12(7):113. doi: 10.1038/s41408-022-00707-4.
2
Cachexia is a risk factor for negative clinical and functional outcomes in patients receiving chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma.
Br J Haematol. 2022 Apr;197(1):71-75. doi: 10.1111/bjh.18054. Epub 2022 Feb 9.
3
Pushing the CART to the Finish Line: Integrating Radiation Therapy Into Chimeric Antigen Receptor T-Cell Therapy Programs to Improve Outcomes for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma.
Int J Radiat Oncol Biol Phys. 2024 Apr 1;118(5):1152-1158. doi: 10.1016/j.ijrobp.2023.03.076. Epub 2024 Mar 14.
4
A ray of hope in a dire situation: Radiotherapy for progression after chimeric antigen receptor T-cell therapy.
Br J Haematol. 2020 Jul;190(1):18-19. doi: 10.1111/bjh.16562. Epub 2020 Mar 4.
5
Safety and feasibility of chimeric antigen receptor T cell therapy after allogeneic hematopoietic cell transplantation in relapsed/ refractory B cell non-Hodgkin lymphoma.
Leukemia. 2019 Oct;33(10):2540-2544. doi: 10.1038/s41375-019-0476-y. Epub 2019 May 21.
6
Allogeneic Stem Cell Transplantation and Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Non-Hodgkin Lymphoma.
Hematol Oncol Clin North Am. 2019 Aug;33(4):687-705. doi: 10.1016/j.hoc.2019.03.005. Epub 2019 May 10.
7
Perceived Cognitive Changes following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?
Transplant Cell Ther. 2023 Jan;29(1):64. doi: 10.1016/j.jtct.2022.09.008. Epub 2022 Sep 21.
8
Response to: Perceived Cognitive Changes Following Chimeric Antigen Receptor T Cell Therapy in Lymphoma: Perceptual Anticipation?
Transplant Cell Ther. 2023 Jan;29(1):65. doi: 10.1016/j.jtct.2022.09.019. Epub 2022 Sep 27.
9
Redefining Non-Hodgkin Lymphoma: Using Genomic Subtypes to Improve Treatment Options.
Hematol Oncol Clin North Am. 2019 Aug;33(4):xiii-xiv. doi: 10.1016/j.hoc.2019.04.005. Epub 2019 May 15.
10
Recent Advances in CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
Clin Lymphoma Myeloma Leuk. 2019 Dec;19(12):751-757. doi: 10.1016/j.clml.2019.09.598. Epub 2019 Oct 2.
引用本文的文献
1
Noncanonical and mortality-defining toxicities of CAR T cell therapy.
Nat Med. 2025 Jul 16. doi: 10.1038/s41591-025-03813-5.
2
Decoding the immune microenvironment of secondary chronic myelomonocytic leukemia due to diffuse large B-cell lymphoma with CD19 CAR-T failure by single-cell RNA-sequencing.
Chin Med J (Engl). 2025 Aug 5;138(15):1866-1881. doi: 10.1097/CM9.0000000000003690. Epub 2025 Jul 7.
3
Development of myeloid neoplasia associated with prolonged immune cell-associated hematotoxicity after CAR T-cell treatment of B-cell lymphoma: Should we surveille for pre-existing myeloid mutations?
Hemasphere. 2025 Jun 5;9(6):e70160. doi: 10.1002/hem3.70160. eCollection 2025 Jun.
4
TP53 -Mutated Myeloid Neoplasms: 2024 Update on Diagnosis, Risk-Stratification, and Management.
Am J Hematol. 2025 Jun;100 Suppl 4(Suppl 4):88-115. doi: 10.1002/ajh.27655. Epub 2025 Mar 11.
5
Immune effector cell-associated hematotoxicity: mechanisms, clinical manifestations, and management strategies.
Haematologica. 2025 Jun 1;110(6):1254-1268. doi: 10.3324/haematol.2024.286027. Epub 2025 Feb 20.
6
T-cell lymphomas in recipients of CAR-T cells: assessing risks and causalities.
Blood. 2024 Dec 12;144(24):2473-2481. doi: 10.1182/blood.2024025828.
7
The Current Landscape of Secondary Malignancies after CAR T-Cell Therapies: How Could Malignancies Be Prevented?
Int J Mol Sci. 2024 Sep 1;25(17):9518. doi: 10.3390/ijms25179518.
8
Second Primary Malignancies after CAR T-Cell Therapy: A Systematic Review and Meta-analysis of 5,517 Lymphoma and Myeloma Patients.
Clin Cancer Res. 2024 Oct 15;30(20):4690-4700. doi: 10.1158/1078-0432.CCR-24-1798.
9
Subsequent Malignancies After CD19-Targeted Chimeric Antigen Receptor T Cells in Patients With Lymphoma.
Transplant Cell Ther. 2024 Oct;30(10):990-1000. doi: 10.1016/j.jtct.2024.06.027. Epub 2024 Jul 6.
10
Late events after anti-CD19 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma.
Front Oncol. 2024 Jun 11;14:1404351. doi: 10.3389/fonc.2024.1404351. eCollection 2024.
本文引用的文献
1
Clonal hematopoiesis in patients receiving chimeric antigen receptor T-cell therapy.
Blood Adv. 2021 Aug 10;5(15):2982-2986. doi: 10.1182/bloodadvances.2021004554.
2
Myelodysplastic syndrome and acute myeloid leukaemia in patients treated with PARP inhibitors: a safety meta-analysis of randomised controlled trials and a retrospective study of the WHO pharmacovigilance database.
Lancet Haematol. 2021 Feb;8(2):e122-e134. doi: 10.1016/S2352-3026(20)30360-4. Epub 2020 Dec 18.
3
Genetic and Genomic Landscape of Secondary and Therapy-Related Acute Myeloid Leukemia.
Genes (Basel). 2020 Jul 6;11(7):749. doi: 10.3390/genes11070749.
4
Assessment of Therapy-Related Myeloid Neoplasms in Patients With Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy: A Systematic Review.
JAMA Oncol. 2020 Jul 1;6(7):1086-1092. doi: 10.1001/jamaoncol.2020.0078.
5
KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma.
N Engl J Med. 2020 Apr 2;382(14):1331-1342. doi: 10.1056/NEJMoa1914347.
6
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells.
Biol Blood Marrow Transplant. 2020 Jan;26(1):26-33. doi: 10.1016/j.bbmt.2019.08.003. Epub 2019 Aug 13.
7
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.
8
Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma.
Leuk Res. 2018 Nov;74:130-136. doi: 10.1016/j.leukres.2018.07.016. Epub 2018 Jul 19.
9
Chimeric Antigen Receptor Therapy.
N Engl J Med. 2018 Jul 5;379(1):64-73. doi: 10.1056/NEJMra1706169.
10
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.
N Engl J Med. 2017 Dec 28;377(26):2531-2544. doi: 10.1056/NEJMoa1707447. Epub 2017 Dec 10.
Zotero 插件